Contents
20 July 2016
Vol 8, Issue 348
Vol 8, Issue 348
Contents
Focus
- A nudge toward participation: Improving clinical trial enrollment with behavioral economics
Interventions informed by behavioral economics can address barriers to patient enrollment in clinical trials and improve recruitment efforts.
Research Articles
- Imaging synaptic density in the living human brain
Synaptic density in the living human brain was measured with positron emission tomography and a synaptic vesicle glycoprotein 2A tracer.
- Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin
The expression of drug transporter OCT2 is suppressed in renal cell carcinoma, and targeting this pathway sensitizes the tumor to oxaliplatin.
- Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
Muscle-directed Smad7 gene delivery prevents the loss of skeletal muscle mass and strength in mouse models of cachexia, an important contributor to poor prognosis in patients with advanced cancer.
Editors' Choice
- Theranostic nanoparticles give the best of both worlds
A fluorescent nanoparticle delivering gene-silencing therapies shows promise for the treatment of anaplastic thyroid cancer.
- Mapping a path for precision cancer therapies
A large-scale pharmacogenomic analysis of human cancer cell lines identifies cancer lineage- and genotype-selective therapies.
- Nature vs. nurture in adipocyte responses to high-fat feeding
Adipose cell proliferation in response to high-fat feeding is regulated by estrogen and the adipocyte microenvironment.
- Insulin delivery never tasted so good
Dual-functionalized nanocarriers survive digestion and trafficking to the bloodstream, suggesting that one dose per day controlled oral insulin delivery may be possible in the future.
About The Cover
ONLINE COVER Seeing Synapses. Many neurological and psychiatric diseases are characterized by misfiring synapses, but there is no way to visualize aberrant neuronal connections in the living brain. Finnema and colleagues developed a noninvasive PET imaging approach to "see" human synapses by using an agent that targets the synaptic vesicle glycoprotein 2A. Such imaging allowed the authors to visualize synaptic density differences in healthy (on cover) and epileptic human brains in living patients. [CREDIT: FINNEMA ET AL./SCIENCE TRANSLATIONAL MEDICINE]
